Cargando...
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience
Ibrutinib is an oral Bruton’s tyrosine kinase (BTK) inhibitor, which has recently gained approval by the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with symptomatic Waldenström macroglobulinemia (WM). Herein, we review...
Gardado en:
| Publicado en: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959643/ https://ncbi.nlm.nih.gov/pubmed/27493708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716654102 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|